McKesson (MCK) recently reported a quarterly revenue shortfall that triggered a notable pullback in its stock price, though social media and analyst chatter highlight robust specialty distribution growth as a potential support factor. The company's shares are currently trading at what some observers describe as an attractive multiple relative to projected profits, suggesting a possible valuation opportunity despite the recent miss. Insider activity has drawn significant attention, with executives including CEO Brian S. Tyler and EVP Michele Lau selling millions of dollars worth of shares over the past six months. While this aligns with typical post-earnings patterns, the lack of insider purchases raises questions about near-term confidence. Conversely, institutional investors show a mixed but active landscape, with major firms like T. Rowe Price reducing positions while others like Barclays and Goldman Sachs increased their holdings significantly. Looking forward, McKesson is preparing for an upcoming Investor Day where users are tracking potential value creation from the planned medical-surgical separation and scaling of its specialty platform. Wall Street sentiment remains cautiously optimistic, with a median price target of $945 set by nine analysts in the last six months, ranging from $812 to $1,050, reflecting a neutral-to-positive outlook on execution risks in a competitive distribution landscape.